Navigation Links
CytRx Reports Promising Data from Its Open-Label Extension Clinical,Trial of Arimoclomol in ALS

ear with a four-fold arimoclomol dose increase, subject to FDA clearance.

"We are encouraged by the favorable results of this open-label trial, which make us even more eager to proceed at an even higher dose level in further clinical testing," stated CytRx's President and CEO Steven A. Kriegsman. "The comparison of these clinical results with historical data suggests a trend toward clinical improvement. Our Phase IIb efficacy study will be placebo-controlled and is planned to include a larger number of volunteers, treated for a longer period of time with a four-fold higher dose than that used in the open-label clinical trial."

The open-label extension clinical trial was initiated in February 2006 as ALS volunteers completing CytRx's placebo-controlled, double-blind, dose-ranging Phase IIa clinical trial were provided the opportunity to receive arimoclomol treatment for up to an additional six months. A total of 69 patients were treated in the open-label arimoclomol trial for six months, while the historical control followed 99 subjects for 12 months.

In the open-label trial, arimoclomol treatment was demonstrated to be safe as indicated by the lack of clinically-significant changes in vital signs and laboratory values, compared to baseline values. Arimoclomol was also well-tolerated with a total drop-out rate of 11.6%, or an average of 1.3% per month, during the six-month trial. This compares favorably with the historical control drop-out rate of 33.3%, or an average of 2.75% per month, for the 12-month trial.

CytRx's planned Phase IIb clinical trial is currently expected to include approximately 390 ALS patients enrolled at 30 to 35 U.S. and Canadian clinical sites treated for nine months. The trial is expected to be completed approximately 18 months after enrollment begins.

About CytRx Corporation

CytRx Corporation is a biopharmaceutical research and development company engaged in the development of high-value human therap
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. CytRx Announces Clinical Results from Its Rising Multiple Dose Trial with Arimoclomol for ALS
2. CytRx Announces RNAi Delivery Nanoparticle Technology Exclusively Licensed to Subsidiary, RXi Pharmaceuticals, Described in Peer-Reviewed Journal
3. CytRx Announces Positive Results of Arimoclomol in Preclinical Stroke Recovery Studies
4. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
5. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
6. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
7. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
8. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
9. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
10. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
11. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
Post Your Comments:
(Date:10/1/2014)... JUPITER, Fla. , Oct. 1, 2014 /PRNewswire/ ... biotechnology company with patented and proprietary technology used ... for the bioenergy, bio-based chemicals, biopharmaceuticals, and industrial ... $500,000 licensing payment from Abengoa Bioenergy for commercial ... for converting biomass into ethanol, developed under Abengoa,s ...
(Date:10/1/2014)... , Oct. 1, 2014 Trovagene, ... diagnostics, announced today that Eli Diamond , ... Cancer Center (MSK), presented clinical data from an ... cancer monitoring platform for the determination of oncogene ... liquid biopsy.  The results were presented to both ...
(Date:10/1/2014)... , Oct. 1, 2014   Royal Philips ... today announced its eCareCoordinator and eCareCompanion telehealth applications ... and Drug Administration (FDA). A part of Philips ... , eCareCoordinator and eCareCompanion are focused on patient ... clinical applications to be available through the cloud-based ...
Breaking Medicine Technology:Dyadic International Reports Licensing Payment For Commercial-Scale Production Of C1-Based Cellulase Enzymes 2Dyadic International Reports Licensing Payment For Commercial-Scale Production Of C1-Based Cellulase Enzymes 3Clinical Performance of Trovagene's Precision Cancer Monitoring Platform Presented at Second Annual International ECD Medical Symposium 2Clinical Performance of Trovagene's Precision Cancer Monitoring Platform Presented at Second Annual International ECD Medical Symposium 3Clinical Performance of Trovagene's Precision Cancer Monitoring Platform Presented at Second Annual International ECD Medical Symposium 4Philips Secures 510(k) Clearance to Market the First Clinical Applications for its new Digital Health Platform 2Philips Secures 510(k) Clearance to Market the First Clinical Applications for its new Digital Health Platform 3Philips Secures 510(k) Clearance to Market the First Clinical Applications for its new Digital Health Platform 4
... (Nasdaq: BIOD ) announced today that the ... development programs have been accepted for poster presentation at ... November 11 and 12, 2010: "Characterization of ... presented by Dr. Frank Flacke, November 12 ...
... -- WuXi PharmaTech (NYSE: WX ), ... and development outsourcing company with operations in China ... had been awarded a Certificate of Good Laboratory ... Drug Administration (SFDA), China,s regulatory authority for pharmaceuticals, ...
Cached Medicine Technology:Biodel to Present Data from Product Development Programs at 2010 Diabetes Technology Meeting 2Biodel to Present Data from Product Development Programs at 2010 Diabetes Technology Meeting 3Biodel to Present Data from Product Development Programs at 2010 Diabetes Technology Meeting 4WuXi PharmaTech Awarded GLP Certificate from SFDA for Suzhou Toxicology Facility 2
(Date:10/1/2014)... (PRWEB) October 01, 2014 Lifeinsurance-policy.com ... find the best life insurance prices for smokers. , ... life insurance premiums. Comparing quotes is the best method ... finding quotes for customers who need coverage. , ... entire duration of the policy. Since the coverage is ...
(Date:10/1/2014)... 01, 2014 Phoseon Technology, the pioneer ... to expand the business worldwide. This rapid growth includes ... capacity for manufacturing efforts. The company has experienced average ... years and expects this growth to continue in the ... gains worldwide adoption. , “We are very pleased ...
(Date:10/1/2014)... 2014 Farmington Company today announced ... mission and visual identity helping brokers, consultants and ... them to create greater benefit communication synergies. They ... on empowering customers to better leverage Farmington Company’s ... jewel of the rebrand is the refreshed tagline: ...
(Date:10/1/2014)... new genetic finding from Duke Medicine suggests that some ... might also be hard-wired to gain weight when exposed ... , An estimated 13 percent of people, all of ... knowing this could help them reduce heart disease with ... stress management. , "Genetic susceptibility, psychosocial stress and metabolic ...
(Date:10/1/2014)... Between 23 million and 50 million people suffer ... from the National Institutes of Health (NIH) and the ... them have something else in common: They have a ... Gluten Free Therapeutics, makers of CeliVites nutritional supplements, ... publishing a series of blog posts aimed at educating ...
Breaking Medicine News(10 mins):Health News:Affordable Whole Life Insurance Premiums for Smokers! 2Health News:Phoseon Technology Continues to Drive Growth Worldwide 2Health News:Farmington Company Launches Rebrand and New Positioning 2Health News:Gene interacts with stress and leads to heart disease in some people 2Health News:Informative New Blog Series Underscores Link Between Celiac Disease and Other Autoimmune Disorders 2Health News:Informative New Blog Series Underscores Link Between Celiac Disease and Other Autoimmune Disorders 3
... WEDNESDAY, Nov. 3 (HealthDay News) -- Higher levels of ... for Medicare patients, a new study has found. ... Information Set revealed wide variation across the United States ... inappropriate prescriptions for the elderly, said the researchers at ...
... Ken Loach has officially opened a new research lab ... and children with hearing difficulties. The Family Lab ... (NIHR) Biomedical Research Unit in Hearing, a partnership between ... the Medical Research Council Institute for Hearing Research. ...
... of Cincinnati (UC) and the Cincinnati Veterans Affairs (VA) Medical ... patients who are prescribed therapies for high blood pressure do ... in the Nov. 2 online edition of the American ... at UC and the Cincinnati VA, showed that treatment of ...
... By Amanda Gardner HealthDay Reporter , WEDNESDAY, ... by commercial plans dropped almost four percentage points between 2008 ... getting vaccinated is rising. "Rates had been gradually improving ... seen a drop -- and it was a pretty big ...
... advantage of the huge variety of medicinal compounds produced ... way to expand plants, pharmaceutical repertoire by genetically engineering ... The researchers, led by Associate Professor Sarah ... enabling it to attach halogens such as chlorine or ...
... deadly disease in the Western world and one of the most ... by a Nottingham academic is aiming to improve our understanding of ... Cancer: A Beginner,s Guide is the first book of its ... a clear and straightforward way, rather than concentrating on just one ...
Cached Medicine News:Health News:Pricey Drugs May Not Mean Better Care 2Health News:Film director launches pioneering hearing research 2Health News:Medication adherence improves blood pressure control in chronic kidney disease 2Health News:Many Higher-Income Parents Forgoing Kids' Vaccinations: Report 2Health News:Many Higher-Income Parents Forgoing Kids' Vaccinations: Report 3Health News:MIT chemists engineer plants to produce new drugs 2Health News:Taking the fear factor out of cancer 2
... 1400 Series Biosafety Cabinets ... revolutionize working in a ... most comfortable, quiet, and ... cabinet on the market, ...
Velcro® Tracheostomy tube holders are available in Adult, pediatric, and infant sizes....
... Your patient will be more comfortable, ... tracheostomy tube stabilization more secure and to ... tying and untying of twill ties, consider ... adult and neonate/infant sizes, the narrow fastener ...
... Designed for ease of use and ... has smooth edges for comfort and is ... one-size-fits-all to a perfect fit. For hard ... a trach collar to your specifications. Don't ...
Medicine Products: